Avanos (AVNS) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.
Need a quote from a Motley Fool analyst? Email [email protected]
The company closed the sale of its hyaluronic acid product line at the end of July 2025, marking a clear step to concentrate resources on its core Specialty Nutrition Systems and Pain Management and Recovery segments. Management maintained guidance for both revenue and adjusted EPS for fiscal 2025, including the impact of the business divestiture, and reiterated confidence in execution across strategic initiatives. The impact of tariffs remains a central factor, with $15 million in incremental costs anticipated for fiscal 2025 and ongoing mitigation efforts focused on supply chain relocation and advocacy.
Source Fool.com
